Maxime Dely: How Do We Balance Benefit and Risk in Chronic Hematologic Diseases?
Maxime Dely, Therapeutic Solutions Sales Consultant at Terumo Blood and Cell Technologies, shared a post on LinkedIn:
“Repeated transfusions: how do we balance benefit and risk in chronic hematologic diseases?
Every year, thousands of patients live thanks to repeated transfusions… but at what long-term cost?
In many chronic hematologic diseases (sickle cell disease, myelodysplastic syndromes, leukemias), red blood cell concentrates are essential to correct anemia
and maintain quality of life.
However, repeated transfusions carry well – documented risks: alloimmunization, making future transfusions more complex, and iron overload, which can lead to hepatic, cardiac, and endocrine complications that are often underestimated.
Iron chelation therapy then becomes necessary, yet burdensome.
Other challenges also arise, such as delayed hemolytic transfusion reactions, sometimes severe, and variability in transfusion thresholds, raising questions about optimal use.
Current guidelines emphasize a more restrictive and individualized approach, tailored to each patient’s condition and disease.
Transfusion is no longer just a supportive act – it is a true therapeutic lever, requiring careful balance between immediate clinical benefit and long-term impact.
Should we more broadly rethink transfusion strategies to better anticipate their chronic consequences?”

More posts featuring Maxime Dely on Hemostasis Today.
-
Sep 11, 2026, 15:17Shadi Tabibian: Where Laboratory Precision Meets Clinical Care
-
Sep 11, 2026, 14:58Kevin Land: Connecting Donors to Patients Across the Spectrum of Care
-
Sep 11, 2026, 14:45Jorge Mascaro: The Growing Impact of the UK Aortic Society on Aortic Disease Care
-
Sep 11, 2026, 14:31Hany Ibrahim: Lp(a) Lowering Meets a Critical Test in the Lp(a)HORIZON Trial
-
Sep 11, 2026, 13:35How Non-Factor Therapies Are Changing Hemophilia Care – Seminars in Thrombosis and Hemostasis
-
Sep 11, 2026, 13:21Emmanuel J Favaloro: Rethinking Quality Control in VWD Testing
-
Sep 11, 2026, 13:10Tessa Youngner: New Free E-Course Introduces Comprehensive SCD Care
-
Sep 11, 2026, 12:55Identifying Key Research Priorities for VTE and Stroke – International Journal of Stroke
-
Sep 11, 2026, 12:43Helping Hematology Employers Reach Qualified Job Seekers – ASH